{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:18:26Z","timestamp":1764829106923,"version":"3.40.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:p>The authors investigated whether there is an association between angiotensin-converting-enzyme inhibitor (ACEI)\/angiotensin II receptor blocker (ARB) users with hemorrhoids. A total of 21,670 ACEI users and 21,670 ARB users during 2000 \u2212 2012 from a national health insurance database were included. Hemorrhoid incidences were monitored to the end of 2013. To examine the risk of hemorrhoids, the Cox proportional hazard model and the Kaplan\u2013Meier method were used. The incidence rate of hemorrhoids in ARB users was 6.64 per 1000 person-years, which was higher than that of the ACEI users (5.48 per 1000 person-years). The adjusted hazard ratio of hemorrhoids in patients who received ACEI relative to those who received ARB was 0.83 (95% confidence intervals [CI] = 0.75, 0.92). Compared to ARB users, patients who used ACEI more than 740 days per year (adjusted hazard ratios = 0.44; 95% CI = 0.36, 0.54) and more than 7800\u2009mg (adjusted hazard ratios = 0.54; 95% CI = 0.46, 0.65) had a lower risk of hemorrhoids. ACEI users who took a relatively long period or high cumulative dosage were found to less prone to develop hemorrhoids.<\/jats:p>","DOI":"10.1097\/md.0000000000033875","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T15:11:26Z","timestamp":1685718686000},"page":"e33875","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers and hemorrhoids: A nationwide, population-based study"],"prefix":"10.1097","volume":"102","author":[{"given":"Wei-Syun","family":"Hu","sequence":"first","affiliation":[{"name":"School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"e282","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America.","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ehj.2004.06.003","article-title":"Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology.","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"Eur Heart J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/CIRCULATIONAHA.105.594945","article-title":"Design of randomized controlled trials.","volume":"115","author":"Stanley","year":"2007","journal-title":"Circulation"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/IJAMH.2009.21.4.485","article-title":"Evidence-based medicine: four fundamental problems with the randomized clinical trial (RCT) used to document chemical medicine.","volume":"21","author":"Ventegodt","year":"2009","journal-title":"Int J Adolesc Med Health"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth.","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"917","DOI":"10.5604\/17322693.1218180","article-title":"The renin-angiotensin-aldosterone system (RAAS) - physiology and molecular mechanisms of functioning.","volume":"70","author":"Chaszczewska-Markowska","year":"2016","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11906-020-1028-6","article-title":"Recent research advances in renin-angiotensin-aldosterone system receptors.","volume":"22","author":"Azushima","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/20009666.2019.1698259","article-title":"Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients.","volume":"9","author":"Anja","year":"2019","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0035-1568144","article-title":"Review of hemorrhoid disease: presentation and management.","volume":"29","author":"Sun","year":"2016","journal-title":"Clin Colon Rectal Surg"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"577767","DOI":"10.3389\/fendo.2020.577767","article-title":"Association of hemorrhoids with hashimoto\u2019s thyroiditis and associated comorbidities: a nationwide population-based cohort study.","volume":"11","author":"Hsu","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.je.2016.12.015","article-title":"Hemorrhoid is associated with increased risk of peripheral artery occlusive disease: a nationwide cohort study.","volume":"27","author":"Hu","year":"2017","journal-title":"J Epidemiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e7662","DOI":"10.1097\/MD.0000000000007662","article-title":"Association between hemorrhoid and risk of coronary heart disease: a nationwide population-based cohort study.","volume":"96","author":"Chang","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s12576-019-00679-4","article-title":"Renin-angiotensin system research: from molecules to the whole body.","volume":"69","author":"Takimoto-Ohnishi","year":"2019","journal-title":"J Physiol Sci"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin\u2013angiotensin system in cardiovascular disease.","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbadis.2016.07.019","article-title":"The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance.","volume":"1863","author":"Ramalingam","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19.","volume":"159","author":"Tan","year":"2020","journal-title":"Gastroenterology"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pds.2087","article-title":"Validation of the national health insurance research database with ischemic stroke cases in Taiwan.","volume":"20","author":"Cheng","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2188\/jea.JE20140076","article-title":"Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan.","volume":"24","author":"Cheng","year":"2014","journal-title":"J Epidemiol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","article-title":"Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan.","volume":"201","author":"Cheng","year":"2015","journal-title":"Int J Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:10:31Z","timestamp":1746324631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":20,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033875","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}